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Abstract 
 
We assessed the effects of post-exercise cold-water immersion (CWI) in modulating PGC-1α mRNA 
expression in response to exercise commenced with low muscle glycogen availability.  In a randomized 
repeated-measures design, nine recreationally active males completed an acute two-legged high-intensity 
cycling protocol (8 x 5 min at 82.5% peak power output) followed by 10 minutes of two-legged post-
exercise CWI (8°C) or control conditions (CON). During each trial, one limb commenced exercise with 
low (LOW: <300 mmol.kg-1 dw) or very low (VLOW: <150 mmol.kg-1 dw) pre-exercise glycogen 
concentration, achieved via completion of a one-legged glycogen depletion protocol undertaken the 
evening prior. Exercise increased (P < 0.05) PGC-1α mRNA at 3 h post-exercise.  Very low muscle 
glycogen attenuated the increase in PGC-1α mRNA expression compared with the LOW limbs in both the 
control (CON VLOW ~3.6-fold vs. CON LOW ~5.6-fold: P = 0.023, ES 1.22 Large) and CWI 
conditions (CWI VLOW ~2.4-fold vs. CWI LOW ~8.0 fold: P = 0.019, ES 1.43 Large).  Furthermore, 
PGC-1α mRNA expression in the CWI-LOW trial was not significantly different to the CON LOW limb 
(P = 0.281, ES 0.67 Moderate). Data demonstrate that the previously reported effects of post-exercise CWI 
on PGC-1α mRNA expression (as regulated systemically via β-adrenergic mediated cell signalling) are 
offset in those conditions in which local stressors (i.e. high-intensity exercise and low muscle glycogen 
availability) have already sufficiently activated the AMPK- PGC-1α signaling axis.  Additionally, data 
suggest that commencing exercise with very low muscle glycogen availability attenuates PGC-1α 
signaling. 
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New & Noteworthy 
 
We demonstrate post-exercise CWI does not enhance the exercise-induced expression of PGC-1α mRNA 
in muscles commencing exercise with low (i.e. <300 mmol.kg-1 dw) or very low (i.e. <150 mmol.kg-1 dw) 
glycogen concentrations.  From a practical perspective, data suggest that the application of post-exercise 
CWI as a strategic training aid for greater PGC-1α mRNA expression is more likely to have beneficial 
effects when utilized after those high-intensity training sessions that have not induced near maximal 
glycogen depletion. 
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Introduction 
 
It is well documented that regular endurance training induces an increase in skeletal muscle mitochondrial 
density (10). At a molecular level, the mitochondrial adaptations induced by endurance training are largely 
regulated via transient increases in mRNA transcripts encoding mitochondrial proteins in response to each 
acute training session (25).  Upon the onset of contraction, homeostatic perturbations within skeletal 
muscle (e.g., increased AMP/ATP ratio, Ca2
+
, reactive oxygen species (ROS), lactate, reduced glycogen 
availability, etc.) result in the activation of regulatory protein kinases that, in turn, activate downstream 
targets such as transcription factors or transcriptional coactivators (21). As a transcriptional coactivator, 
the peroxisome proliferator-activated receptor coactivator (PGC-1α), has been the focus of intense 
investigation during the last two decades and is repeatedly cited as the “master regulator of mitochondrial 
biogenesis” (3, 28).  The importance of PGC-1α in regulating mitochondrial content and function is 
evident from rodent studies demonstrating that overexpression increases oxidative enzyme activity (20), 
improves insulin sensitivity (5), protects against sarcopenia (34) and also improves exercise capacity (6).  
In relation to human skeletal muscle, multiple laboratories have examined the potential to augment the 
adaptive response to a given exercise stimulus through interventions that modulate and enhance the 
exercise-induced activation of the PGC-1α signaling axis.  Consistent with the initial discovery that PGC-
1α was cold-inducible in rodent skeletal muscle (29), we (2,17) and others (13,14) have demonstrated that 
both passive and post-exercise cold-water immersion (CWI) enhances the acute expression of PGC-1α 
mRNA (17), an effect that is likely regulated systemically (via β-adrenergic activation of local cell 
signaling pathways), as opposed to local cooling effects per se (2).  In accordance with the acute effects 
of CWI, chronic application of the CWI stimulus in response to consecutive training sessions up-regulates 
chronic markers of training adaptations such as lipid enzyme activity and oxidative enzyme protein content 
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(14).    
In addition to CWI, we (4, 15) and others (36, 33, 12, 27) have also demonstrated a potent role of reduced 
muscle glycogen availability in enhancing the chronic adaptations to endurance training, an effect that is 
also associated with the augmented activation of the AMPK- PGC-1α signaling axis in response to an 
acute training session that is completed with reduced CHO availability before, during and/or after exercise 
(16).  This body of work is often communicated as the train-low (smart): compete high paradigm surmising 
that carefully selected training sessions could be completed with reduced CHO availability so as to 
augment training adaptation, yet competition should always be commenced with high CHO availability 
so as to promote optimal performance.  When taken together, such data raise the possibility that 
simultaneous application of post-exercise CWI and reduced CHO availability may augment the cell 
signaling responses associated with the regulation of mitochondrial biogenesis, when compared with the 
application of either stimulus in isolation.  However, given recent data highlighting the role of local muscle 
metabolic stress in modulating acute exercise-induced cell signaling pathways (7), it is suggested that the 
application of CWI (i.e. a systemic mediated stress) induces negligible regulatory effects on a muscle that 
has already been subjected to the extreme local metabolic challenge of both high-intensity exercise and 
low muscle glycogen availability. 
 
Accordingly, the aim of the present study was to assess the effects of post-exercise CWI in modulating 
the regulation of PGC-1α mRNA expression in muscles that have already completed the challenge of high-
intensity exercise and low muscle glycogen availability.  Using a prior glycogen manipulation protocol, 
we adopted an experimental design where subjects completed an acute two-legged high-intensity cycling 
protocol with and without two-legged post-exercise CWI but where each limb commenced exercise with 
low (<300 mmol.kg-1 dw) or very low (<150 mmol.kg-1 dw) pre-exercise glycogen concentration.  In this 
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way, we were able to obtain muscle biopsies from four limbs subjected to the same exercise stimulus but 
with differing local (i.e. pre-exercise glycogen availability) and systemic stressors (i.e. CWI versus non-
cooling conditions).   
 
 
Materials and Methods 
 
 
Participants: Nine recreationally active healthy males (age 22 ± 3 yrs.; body mass 74.18 ± 7.88 kg; height 
180.50 ± 6.60 cm; peak power output (PPO) 272 ± 256 W; mean ± SD) participated in this study. 
Participants were instructed to refrain from exercise, alcohol and caffeine 48 hours prior to the first 
depletion protocol, and not to stray from the prescribed meal plan or exercise within the 48 hours 
preceding the experimental day. All procedures performed in the study were approved by the Ethics 
Committee of Liverpool John Moores University and in accordance with the 1964 Helsinki declaration 
and its later amendments. 
 
Preliminary testing: Prior to commencing the experimental trials the participants completed an 
incremental exercise test to fatigue for the determination of V̇ O2peak and PPO (as described in detail in 
8). Results from this test were used to determine the Watts necessary for cycling at a proportion of PPO 
on subsequent test days. PPO was calculated using the equation below (24); where CB is the wattage of 
the last complete bout, FB is the fraction of the final bout completed, and 25 is the increment of 25W 
between each successive bout: PPO = CB + (FB x 25). Further preliminary visits encompassed 
familiarisation to the glycogen depletion protocols to be completed prior to the experimental day. 
 
Experimental design: In a repeated-measure, randomised crossover design, with at least 14 d between 
trials, participants reported to the laboratory a total of nine times, where the first three were familiarisation 
sessions. In order to establish a research design that allowed the investigation of 4 separate conditions 
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from 2 visits participants underwent a single-leg depletion protocol and bi-lateral muscle biopsies with 
and without post-exercise CWI to give the following conditions: Low glycogen control (CON LOW), Very 
Low glycogen control (CON VLOW), Low glycogen CWI (CWI LOW) and Very Low glycogen CWI 
(CWI VLOW) (See Figure 1). 
 
Two-legged glycogen depletion, Visit 1: Participants arrived at the laboratory 40 h prior to the 
experimental trial at 1600 h and undertook a 5-min warm-up at 100 W. From here, participants performed 
an intermittent cycling protocol aimed to deplete both limbs of muscle glycogen. A two-legged glycogen 
depleting cycling protocol consisting of 2 min at 90% PPO, followed immediately by a 2-min recovery 
period at 50% PPO. Participants repeated this work to rest ratio until 2 min cycling at 90% PPO could not 
be maintained, determined as an inability to maintain a cadence of 70 rev.min-1. At this point, exercise 
intensity was lowered to 80% PPO, with the same work to rest ratio. When participants could no longer 
maintain this intensity, it was lowered to 70% and then finally to 60% PPO with the same work to rest 
ratio. When the participants were unable to cycle for 2 min at 60% PPO, the exercise protocol was 
terminated. This intermittent pattern of exercise has previously been shown to evoke glycogen depletion 
in both type I and type II fibres (19). After the completion of the two-legged glycogen depletion protocol, 
participants were provided with a high CHO diet for the next ~22 h (CHO 8 g·kg-1 body mass, protein 
(PRO) 1.4 g·kg-1 body mass, Fat 0.5 g·kg-1 body mass).  Feeding began immediately after the cessation 
of exercise for 4 x hourly intervals that evening. Participants were also provided with breakfast for the 
following morning and returned to the laboratory post-breakfast to collect food for the rest of the day (~8g 
CHO·kg-1 body mass). The purpose of this initial glycogen depletion protocol with high CHO refeed was 
to ensure participants had a similar bi-lateral concentration of muscle glycogen prior to commencing the 
second evening depletion. 
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Single-leg glycogen depletion, Visit 2: Approximately 15 h prior to the experimental trial, participants 
attended the laboratory for a single-leg glycogen depletion protocol to deplete their dominant leg only. 
Glycogen depletion of the dominant leg was undertaken as to ensure similar muscle recruitment patterns 
and therefore glycogen depletion between trials. Single-leg glycogen depletion involved 20 min 
continuous single-leg cycling at 75% PPO, followed by intermittent cycling at a work to rest ratio of 
90s:90s. Intermittent cycling began at 90% PPO decreasing in 5% decrements when such a workload 
could not be maintained for 5 s consecutively. Exercise ceased when 55% PPO could not be maintained 
for 5 s consecutively. Immediately following this, the participants completed an all-out one-legged 
cycling bout at 85% PPO before going on to 30 minutes of 2-arm cycling at 50W in an attempt to decrease 
liver glycogen levels and therefore diminish the potential for muscle glycogen resynthesis (26). 
Participants then underwent an overnight fast before returning to the lab the next day.   
 
Experimental trial, Visit 3: Upon arrival at the laboratory participants were fitted with a heart- rate belt 
(Polar RS400, Kempele, Finland), skin and rectal temperature probes (MHF-18050-A and MRV-55044-
A, Ellab, Rodovre, Denmark) and legs were marked for subsequent insertion of muscle temperature 
needles. Following 10-minutes in a supine position baseline measures of HR, temperature and oxygen 
uptake (V̇O2; Oxycon Pro, Jaeger, Wuerzberg, Germany) were assessed. Resting venous blood 
samples were drawn from a superficial vein in the anti-cubital crease of the forearm using venepuncture 
cannulation (BD Nexiva Closed IV Catheter 22G Blue, Becton Dickinson, Oxford, UK). Resting muscle 
temperature was assessed using a needle thermistor (13050; Ellab, Rodovre, Denmark) before resting bi-
lateral muscle biopsies were sampled from the vastus lateralis (~30-50 mg wet wt). Immediately after 
the resting biopsy participants completed a high-intensity intermittent cycling protocol, consisting of 8 
× 5 min bouts at 82.5% PPO separated by 1 min rest followed by either two-legged CWI (CWI: 10 
min at 7.96 ± 1.05°C) or a control condition (CON; seated rest). From here, participants recovered in 
9  
a semi-reclined position under normal laboratory temperatures until 3-hours post-exercise. Measures of 
heart rate, skin temperature (thigh and calf) and rectal temperature were recorded throughout the exercise 
and recovery periods. Oxygen uptake was measured during the final minute of each high-intensity bout 
of exercise, during immersion and immediately post-immersion to assess for shivering thermogenesis 
and again at 1, 2 and 3h post-exercise.  
 
Laboratory temperatures remained stable throughout (~21°C) and at no point were participants allowed 
to rub themselves dry or shower (changing into dry clothes after immersion was allowed). Muscle 
temperature was assessed post-exercise, 1, 2 and 3h post-exercise, whilst venous blood samples were 
also drawn at these times. Further bi-lateral muscle biopsies occurred immediately after exercise and 
3h post- exercise in line with previous research (2, 3, 13, 15, 17). Biopsies were obtained from both 
limbs at all time points to allow for comparison between low (LOW) and very low (VLOW) glycogen 
limbs in both CON and CWI trials. All incisions were individually anaesthetised, separated distally by 2-
3 cm and included four passes of muscle tissue per biopsy. 
 
Blood analysis: All samples were analysed in duplicate. Samples were analysed for serum glucose, 
lactate, NEFA, and glycerol concentration using commercially available kits (Randox Laboratories, 
Antrim, UK). Plasma metanephrine and Normetanephrine concentrations were measured using liquid 
chromatography tandem mass spectrometry as previously described (23). Serum samples were also 
analysed for insulin using a solid phase enzyme-linked immunosorbent assay (ELISA, KAQ1251, Life 
Technologies, UK), according to manufacturer’s instructions. 
 
Muscle glycogen: Muscle glycogen concentration was determined according to the method described by 
Van Loon et al. (32). Approximately 2-3 mg of freeze-dried sample was dissected free of all visible non-
10  
muscle tissue and subsequently hydrolysed by incubation in 500 μl of 1 M HCl for 3-4 hours at 100°C. 
After cooling to room temperature, samples were neutralized by the addition of 250 μl 0.12 mol.L-1 KOH 
saturated with KCl. Following centrifugation, 150 μl of the supernatant was analysed in duplicate for 
glucose concentration according to the hexokinase method using a commercially available kit (GLUC-
HLK, Randox Laboratories, Antrim, UK). Glycogen concentration is expressed as mmol·kg-1dw and 
intra assay coefficients of variation was <5%. 
 
RNA isolation and extraction: 200µl of chloroform was added per 1 ml TRIzol reagent used during 
homogenisation and shaken vigorously by hand for 15 seconds before being incubated at room 
temperature for 3 minutes. Samples were then centrifuged at 12000 g for 15 minutes at 4°C. After 
centrifugation, the samples were separated into their red phenol, middle interphase and upper aqueous 
phase. The upper aqueous phase was carefully removed into a clean, labelled RNA/DNA free Eppendorf, 
ensuring the middle interphase was not disturbed, and mixed with 500µl isopropanol (per 1 ml TRIzol). 
After vortex for 15 s, the sample was incubated at room temperature for 10 minutes before further 
centrifugation (12000 g for 10 minutes at 4°C). The resulting supernatant was removed and the remaining 
RNA pellet washed in 1 ml ice- cooled 75% ethanol (per 1 ml TRIzol), vortexed briefly before 
centrifugation at 7500 g for 8 minutes at 4°C. The ethanol was subsequently removed and the RNA pellet 
allowed to air dry before re-suspension in 30 µl RNA storage solution (Invitrogen, UK). Samples were 
incubated in a block heater at 50°C for 10 minutes to assist with re-suspension before proceeding to 
measurement. RNA concentration and purity were assessed by UV spectroscopy at optical densities 
of 260 and 280 nm with the use of a Nanodrop 2000 (Thermo Fisher Scientific, UK). A target of 
A260 / A280 ratio was set at 2.0. 70 ng RNA was used for each polymerase chain reaction (PCR) reaction. 
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Primer Design: Primer       sequences       (Table       1)       were       identified        using       Gene (NCBI, 
http://www.ncbi.nlm.nih.gov.gene) and   designed   using   Primer-BLAST (NCBI, 
http://www.ncbi.nlm.nih.gov/tools/primer-blast). Sequence homology searches ensured specificity. The 
primers were ideally designed to yield products spanning exon-exon boundaries to prevent any 
amplification of gDNA. Three or more GC bases in the last five bases at the 3’ end of the primer was 
avoided. Secondary structure interactions (hairpins, self-dimer and cross dimer) within the primer were 
avoided. All primers were between 16 and 25 bp, and amplified a product of between 67 – 212bp. Primers 
were purchased from Sigma (Suffolk, UK). 
 
Gene Expression analysis by real time-quantitative reverse transcriptase polymerase chain reaction rt-
qRT-PCR: rt-qRT-PCR amplifications were performed using QuantiFast
TM
SYBR
® Green RT-PCR one-
s t e p  kit on a Rotor-gene 3000Q (Qiagen, Crawley, UK) supported by rotor-gene software 
(Hercules, CA, USA). rt-qRT-PCR was performed as follows: hold 50°C for 10 min (reverse 
transcription/cDNA synthesis), 95°C for 5 min (transcriptase inactivation and initial denaturation step) 
and PCR steps of 40 cycles; 95°C for 10s (denaturation) and 60°C for 30s (annealing and extension). 
Upon completion, dissociation/melting curve analysis were performed to reveal and exclude non-specific 
amplification or primer-dimer issues (all melt analysis in this study presented single reproducible peaks 
for each target gene suggesting amplification of a single product). Following initial screening of suitable 
reference/housekeeping genes, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) showed the most 
stable Ct values across all RT-PCR runs, participants and regardless of experimental condition (27.02 ± 
1.96 CT; 7% Co-efficient of variation) and was selected as the reference gene in all RT-PCR assays. The 
relative gene expression levels were calculated using the comparative Ct (
ΔΔ
Ct) equation (30) where the 
relative expression was calculated as 2-
ΔΔCt and where Ct represents the threshold cycle. mRNA 
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expression for all target genes was calculated relative to the reference gene (GAPDH; participants own 
reference, not pooled) within same subject and condition and to a calibrator of pre-exercise. The average 
PCR efficiency was 91.25% and variation for all genes (including the reference gene) was less than 
6.3%.  
 
Statistical analysis: All data are presented as mean ± SD. Baseline data, distance cycled, exercise HR and 
RPE were compared between conditions using a Paired Samples T-test. A two-way (4 conditions x 
time) within participant’s general linear model for condition (CON LOW, CON VLOW, CWI LOW, 
CWI VLOW) and time was used to evaluate muscle glycogen, thigh skin temperature, muscle temperature 
and gene expression. A two-way (2 conditions × time) within-participants general linear model was used 
to evaluate all blood measures (glucose, lactate, NEFA, glycerol, insulin, normetanephrine, 
metanephrine), rectal temperature, subjective and physiological responses (HR, RPE, shivering, V̇  O2). 
The main effects for condition and time were followed up using planned LSD multiple comparisons. The 
ES magnitude was classified as trivial (<0.2), small (>0.2-0.6), moderate (>0.6-1.2), large (>1.2-2.0) 
and very large (>2.0-4.0) (11). The α level for evaluation of statistical significance was set at P < .05. 
 
 
Results 
 
Day 1 and 2: Glycogen depletion exercise protocols 
 
In the two-legged glycogen depletion protocol undertaken on the evening of Day 1, no difference was 
observed between conditions for distance cycled (CON 67.1 ± 18.1 km, CWI 67.3 ± 6.1 km, P = 0.394, ES 
0.01 Trivial), time to depletion (CON 134 ± 30 min, CWI 130 ± 12 min, P = 0.669, ES 0.19 trivial) or 
number of intervals completed (8 ± 2 per stage for both CON and CWI, P = 0.669, ES 0.20 Small). In 
the single-leg glycogen depletion protocol undertaken on the evening of Day 2, no significant difference 
13  
was present between conditions for distance cycled in the 20-minute steady-state period (CON 9.5 ± 
1.2 km, CWI 8.5 ± 0.9 km, P = 0.194, ES 1.09 Moderate), number of subsequent high intensity bouts 
completed (CON 6.8 ± 2.0 per stage, CWI 6.4 ± 2.0 per stage, P = 0.235, 0.18 Trivial) and the distance 
cycled during the intervals (CON 47.5 ± 8.8 km, CWI 47.9 ± 7.3 km, P = 0.587, ES 0.06 Trivial). 
Moreover, no differences were observed between conditions for time (CON 40.7 ± 9.0s, CWI 37.5 ± 
8.4s) and distance (CON 0.6 ± 0.2 km, CWI 0.4 ± 0.1 km) completed in the all-out exhaustive one-leg 
cycle (P = 0.197 ES 0.38 Small and 0.094 ES 0.94 Moderate, respectively).   
 
Day 3: Main experimental trial 
 
Physiological responses to exercise  
 
Distance cycled during the two-legged high-intensity intermittent cycling protocol (CON 26.8 ± 2.8 km, 
CWI 26.7 ± 3.4 km; P = 0.946, ES 0.01 Trivial), heart rate (P = 0.992, ES 0.004 Trivial), V̇O2 (ml·kg-1·min-
1; P = 0.602, ES 0.24 Small) and RPE (P = 0.849, ES 0.07 Trivial) were similar between CON and CWI 
trials (data not shown). Mean HR during the final minute of exercise was 179 ± 7 beats.min-1 in CON and 
177 ± 9 beats.min-1 in CWI (P > 0.05), equating to ~80% HR max. The RPE in the final exercise bout 
was 20 AU and 19 AU in the CON and CWI trials respectively. Such data highlight that the distance 
cycled and both whole body physiological / perceptual responses were comparable between the control 
and CWI trials. 
 
Muscle glycogen concentration 
 
Muscle glycogen concentrations were lower in the VLOW limbs compared to the LOW limbs in both 
the control (CON LOW vs. CON VLOW: P = 0.017, ES 1.04 Moderate) and CWI trials (CWI LOW vs. 
CWI VLOW: P = 0.001, ES 1.18 Moderate; Figure 2). In contrast, the concentration of muscle glycogen 
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was similar between the respective LOW (CON LOW vs. CWI LOW: P = 0.819, ES 0.07 Trivial) and 
VLOW conditions (CON VLOW vs. CWI VLOW: P = 0.751, ES 0.14 Trivial; Figure 2). Muscle glycogen 
decreased immediately following exercise (P = 0.001, ES 1.11 Moderate) and at 3 h post-exercise (P = 
0.008, ES 1.10 Moderate) compared to pre-exercise values, the magnitude of which did not differ 
between trials (P = 0.116).  Such data confirm that the intended aim of obtaining both LOW (i.e. <300 
mmol.kg-1 dw) and VLOW (i.e. <150 mmol.kg-1 dw) pre-exercise muscle glycogen concentrations was 
achieved in both the control and CWI trials. 
 
Physiological and shivering responses to CWI versus control conditions 
 
Heart rate was similar between conditions (P = 0.584, ES 0.18 Trivial) during the immersion and 
recovery period (see Table 2). The change in HR over time was also similar between conditions (P = 
0.137), declining during the post-immersion period in both conditions. During the same period, oxygen 
uptake was greater in CWI vs. CON (P = 0.014, ES 1.83 Large).  The change in V̇O2 over time was also 
different between conditions (P = 0.045) with increases in V̇O2 occurring during the initial 2 minutes 
of immersion. Following CWI, V̇O2 decreased below pre- immersion values and remained lower 
throughout the 3 h recovery period (ES >0.58 Small) (P < 0.05). Subjective ratings of shivering were 
greater in CWI (P = 0.052, ES 0.94 Moderate). The change in subjective ratings of shivering over time 
also tended to be greater in CWI with values increasing during immersion and the 10-minute period 
immediately post-immersion (P = 0.089) (Table 2). 
 
Thermoregulatory responses to CWI versus control conditions 
 
 
Rectal temperature (Trec) was similar between conditions (P = 0.887, ES 0.02 Trivial) during exercise 
and post-exercise recovery (see Figure 3A). During the immersion and recovery period, Trec decreased 
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from the fifth minute of immersion until 3 h post-exercise (P < 0.001). Thigh skin temperature (Tthigh) 
was lower during immersion and the post-immersion period in CWI vs. CON conditions (P < 0.001, ES 
2.48 Very Large). The change in Tthigh over time was also different between conditions, with Tthigh 
continually decreasing during cooling in CWI conditions, remaining lower than pre-immersion values 
at 3 h post exercise (P = 0.001, see  Figure 3B). Muscle temperature (Tmus) was lower following 
immersion (P <0.001) in the CWI limbs (P < 0.001, ES 0.90 Moderate). The change in Tmus over time 
was also different between conditions. Muscle temperature declined to a large extent immediately after 
immersion in the CWI limb, followed by a further gradual reduction during the remaining 3h post-
exercise period (P < 0.001, ES 1.0 Moderate, see Figure 3C). 
Circulating plasma metabolites and catecholamines 
 
 
There was no significant difference in plasma glucose, lactate, NEFA, insulin and glycerol 
concentrations between conditions (P > 0.05) (Table 3). The change in these parameters over time was 
also similar between conditions (P > 0.05). Exercise-induced significant increases in glucose, lactate, 
glycerol and NEFA (P < 0.05). Metanephrine concentrations were similar between conditions (P = 0.955, 
ES 0.02 Trivial, Table 3). The change in metanephrine over time was also similar between conditions (P 
= 0.438). Metanephrine concentration was increased post-exercise (P < 0.001, ES 2.10 Very Large) 
and remained above baseline at 1h post-exercise (P = 0.02, ES 0.59 Small). Normetanephrine 
concentrations were similar between conditions (P = 0.130, ES 0.14 Trivial, Table 3). The change in 
normetanephrine over time was different between conditions, with normetanephrine concentrations 
decreasing to a greater extent in CON during the 3h post- exercise period (P = 0.026, ES 1.60 Large). 
Normetanephrine concentration increased post- exercise (P = 0.002, ES 1.50 Large) and remained above 
baseline in CWI conditions until 2h post-exercise (P < 0.05; P = 0.058). 
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Skeletal muscle mRNA responses 
 
Exercise increased PGC-1α mRNA at 3 h post-exercise in all conditions (P < 0.001; ES 1.99 
Large) (Figure 4). At 3 h post-exercise, PGC-1α mRNA expression was attenuated in the VLOW 
limbs compared with the LOW limbs in both the CON (CON VLOW vs. CON LOW: P = 0.023, 
ES 1.22 Large) and CWI conditions (CWI VLOW vs. CWI LOW: P = 0.019, ES 1.43 Large; 
P = 0.039).  This reflected the greater change in expression in the LOW limbs in both CON and 
CWI conditions between post-exercise and 3 h post-exercise time points (P =0.034).  There was 
no significant difference in PGC-1α mRNA expression between the CWI LOW limb and CON 
LOW limb at 3 h post-exercise  (P = 0.281, ES 0.67 Moderate;) (Figure 4). In contrast to PGC-
1α, the expression of COXIV, CS, TFam, SIRT1, NRF2 and GLUT4 mRNA (Figure 5) did not 
change in response to exercise or CWI (P > 0.05). 
 
 
Discussion  
 
The rationale for the present study was based on previous observations that both post-exercise CWI 
(2, 13, 14, 17) and reduced muscle glycogen availability (4, 15) independently augment the exercise-
induced mRNA expression of the master regulator of mitochondrial biogenesis, PGC-1α.  
Accordingly, it is tempting to speculate that the application of both stressors simultaneously amplifies 
the adaptive responses of skeletal muscle to exercise, when compared with either intervention alone.  
In contrast, given recent data highlighting the role of local metabolic stress in modulating acute 
exercise-induced cell signaling pathways (7), we hypothesised that the application of CWI (i.e. a 
systemic mediated stress) induces negligible regulatory effects on muscles that have already been 
subjected to the extreme local metabolic challenge of both high-intensity exercise and low muscle 
glycogen availability.  Confirming our hypothesis, we demonstrate that the application of post-exercise 
CWI does not enhance the exercise-induced expression of PGC-1α mRNA in muscles that completed 
17  
an acute high-intensity cycling protocol with low (i.e. <300 mmol.kg-1 dw) or very low (i.e. <150 
mmol.kg-1 dw) pre-exercise muscle glycogen concentrations.  From a practical perspective, our data 
suggest that the application of post-exercise CWI as a strategic training aid for greater PGC-1α gene 
expression is more likely to have beneficial effects when utilized after those high-intensity training 
sessions that have not induced near maximal glycogen depletion. 
 
In our previous study (2), we utilised the same exercise protocol as that studied here (i.e. 8 x 5 min at 
82.5% PPO) and demonstrated that post-exercise CWI (10 minutes of single limb immersion at 8°C) 
augments PGC-1α mRNA expression (9-12-fold) in both the immersed and non-immersed limbs 
when compared with biopsies obtained from an exercise only trial after which no post-exercise CWI 
occurred (5-fold).  In using that specific design, these data suggested that the effects of post-exercise 
CWI previously observed by our laboratory (17) and others (13, 14) is regulated systemically via β-
adrenergic activation of AMPK (2) and/or cAMP-CREB-PGC-1α signaling (1), as opposed to local 
cooling effects per se. In the present study, we recruited a similar subject population to complete the 
same two-legged exercise protocol studied previously but in conditions where each limb commenced 
exercise with low (<300 mmol.kg-1 dw) or very low (<150 mmol.kg-1 dw) muscle glycogen 
availability.   Additionally, we also adopted a two-legged post-exercise CWI protocol as opposed to 
the single limb immersion protocol studied previously (2).   Indeed, given that the magnitude of 
sympathetic discharge to skeletal muscle is influenced by both the size of the tissue area exposed to 
cooling (31) as well as the magnitude of the cooling stimulus (18), it is noteworthy that the two-
legged immersion protocol studied here elicited almost double the stress response as to that observed 
previously in response to single limb immersion (i.e. Normetanephrine ~919 vs. ~517 pmol·L-1 at 3 
h post-exercise).  Nonetheless, despite the enhanced cooling stimulus and adrenergic response 
observed here, we observed no augmented effects of post-exercise CWI on PGC-1α mRNA 
expression in either the LOW or VLOW limbs.  When taken together, it could be suggested that the 
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systemic effects of post-exercise CWI (i.e. β-adrenergic activation of AMPK and/or cAMP-CREB-
PGC-1α) induces negligible effects on the regulation of PGC-1α mRNA expression when the relevant 
upstream signaling cascade(s) has already been activated by the combination of high-intensity 
exercise and low muscle glycogen availability (i.e. glycogen mediated AMPK-PGC-1α signaling). 
 
Surprisingly, one of the most novel aspects of the present study was the finding that the magnitude 
of the exercise-induced changes in PGC-1α was reduced in the VLOW limbs compared with the 
LOW limbs, a finding that was evident in both the CWI and control trials.  It is difficult to offer a 
definitive explanation for this finding but we suggest two related reasons. Firstly, given that Ca2+ 
release from the sarcoplasmic reticulum (SR) is significantly impaired in glycogen depleted fibres 
(i.e. <150 mmol.kg-1 dw) (22), it is possible that force production was lower in the VLOW limbs 
when compared with the LOW limbs.  As such, subjects may have exhibited greater muscle fibre 
recruitment in the LOW limbs when compared with the VLOW limbs in order to induce a 
compensatory effect to maintain gross cadence and power output.  In this way, a lower PGC-1α 
response (as detected in whole muscle homogenates) in the VLOW limbs may simply be explained 
by lower absolute muscle fibre recruitment.  Alternatively, the potential reduction of SR Ca2+ release 
within specific muscle fibres (22) may actually reduce Ca2+ mediated regulation of the cyclic AMP 
response element of the PGC-1α promoter owing to reduced upstream signaling through p38 MAPK, 
CaMKII and CREB (35).  Unfortunately, we cannot currently offer definitive support for this 
hypothesis given that we did not quantify muscle fibre recruitment of the vastus lateralis muscles of 
both the LOW or VLOW limbs, nor did we measure the activation status of the aforementioned 
signaling proteins in either whole muscle homogenate or specific muscle fibres. Nonetheless, the 
suggestion that extremely low muscle glycogen availability may impair exercise-induced cell 
signaling (as opposed to enhance signaling) lends support for the recently proposed muscle glycogen 
threshold hypothesis (9) surmising that cell signaling processes are particularly responsive within a 
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given range of absolute pre- to post-exercise muscle glycogen concentrations (e.g. 300 to 100 
mmol.kg-1 dw). 
 
Importantly, the VLOW glycogen limbs underwent depleting exercise the night before the experimental 
day, whilst the LOW limbs did not. This may therefore have led to higher absolute pre-exercise mRNA 
values in the VLOW vs. LOW glycogen limbs, ultimately lowering the potential fold changes seen at 3h 
post exercise when compared with pre-values. It is important to highlight that gene expression in the 
present study was calibrated to the limbs own PRE value. As such, it is sensible to suggest that the 
lower values noted for PGC-1α mRNA expression in the VLOW vs. LOW limbs might be a factor of 
this calibration and higher basal levels in the VLOW limbs. Indeed, exploring further and calibrating 
all PGC-1α mRNA data to CON LOW Pre-Exercise the difference between LOW and VLOW 
conditions is no longer statistically significant (P > 0.05). However, despite this, it still remains that 
post-exercise CWI was unable to augment PGC-1α mRNA above the exercise response, in the 
expected manner for LOW and VLOW conditions. This supports the earlier point that the muscle 
may have already been exposed to sufficient levels of metabolic stress via extremely low glycogen 
availability and therefore any additional stress from the cold is unable to augment PGC-1α mRNA 
further. This further exploration is not surprising given the low availability of glycogen in both LOW 
and VLOW conditions. 
 
In summary, we provide novel data demonstrating that the previously documented effects of post-
exercise CWI in modulating PGC-1α mRNA expression in human skeletal muscle are not apparent 
when exercise is commenced with very low muscle glycogen availability.  Such data suggest that any 
potential effect of systemically mediated regulation of PGC-1α mRNA expression is negligible when 
muscles have already been exposed to sufficient local signaling events that arise during exercise.  
Additionally, the presence of extremely low muscle glycogen availability may actually impair 
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exercise-induced cell signaling processes.  From a practical perspective, our data suggest that athletes 
are more likely to obtain beneficial PGC-1α gene expression from post-exercise CWI protocols when 
utilized after those high-intensity interval-training sessions that have not induced near maximal 
glycogen depletion. 
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TABLES 
 
 
Table 1: Primer sequences used for real-time PCR. 
 
Gene Forward Primer Reverse Primer Product Length 
(base pairs) 
GAPDH 
NM_002046.5 
AAGACCTTGGGCTGGGACTG TGGCTCGGCTGGCGAC 168 
PGC-1alpha 
NM_013261.3 
TGCTAAACGACTCCGAGAA TGCAAAGTTCCCTCTCTGCT 67 
p53 
NM_000546.5 
ACCTATGGAAACTACTTCCTGAAA CTGGCATTCTGGGAGCTTCA 141 
SIRT1 
NM_012238.4 
CGGAAACAATACCTCCACCT CACATGAAACAGACACCCCA 186 
COXIV 
NM_001861.4 
CGAGCAATTTCCACCTCTGT GGTCACGCCGATCCATATAA 94 
CS 
NM_004077.2 
CCTGCCTAATGACCCCATGTT CATAATACTGGAGCAGCACCCC 137 
TFAM 
NM_003201.2 
TGGCAAGTTGTCCAAAGAAACCTGT GTTCCCTCCAACGCTGGGCA 135 
 
NRF2 
NM_002040.3 
 
AAATTGAGATTGATGGAACAGAGAA 
 
TATGGCCTGGCTTACACATTCA 
 
95 
 
ERRα 
NM_004451.4 
 
TGCCAATTCAGACTCTGTGC CCAGCTTCACCCCATAGAAA 
 
212 
GLUT4 
NM_001042.2 
TCTCCAACTGGACGAGCAAC CAGCAGGAGGACCGCAAATA 101 
 
Glyceraldehyde 3-phosphate dehydrogenase –GAPDH; Peroxisome Proliferator-activated receptor 
gamma coactivator 1-alpha – PGC-1α; Tumour suppressor protein 53- p53; Sirtuin 1 – SIRT1; 
Cytochrome C oxidase subunit 4 – COXIV; Citrate synthase – CS; Mitochondrial transcription factor A 
– TFAM; Nuclear respiratory factor 2 – NRF2; Estrogen-related receptor alpha – ERRα; Glucose 
transporter type 4 – GLUT4. 
 
 
 
 
 Table 2: Heart rate (n=9), oxygen uptake (n=8) and subjective shivering measures (n =9) during immersion and the post-immersion period 
(mean ± SD). 
 
     Immersion     Post-Immersion      
  
PreIm 2min 4min 6min 8min 10min 2min 4min 6min 8min 10 
min 
1h 2h 3h 
HR  
(beats.min-1) 
CON 84 
±5 
81 
±4 
82 
±2 
80 
±3 
78 
±5 
82 
±7 
84 
±5 
83 
±5 
80 
±6 
82 
±5 
80 
±4 
79 
±5 
76 
±8 
74 
±7 
 
CWI 95 
±19 
110 
±20 
94 
±6 
85 
±12 
81 
±4 
89 
±18 
79 
±10 
76 
±9 
74 
±8 
76 
±11 
80 
±11 
78 
±9 
69 
±9 
73 
±12 
V̇ O2  
(ml·kg-1·min-1) 
CON 5.4 
±0.8 
5.0 
±0.7 
4.7 
±0.6 
4.6 
±0.7 
4.4 
±0.6 
4.6 
±0.6 
4.7 
±0.6 
4.5# 
±0.7 
4.3# 
±0.5 
4.9# 
±0.8 
4.7# 
±0.7 
4.6# 
±0.6 
4.6# 
±0.8 
4.2# 
±0.7 
 CWI 8.5 
±2.0 
9.7 
±2.1 
9.0 
±1.6 
8.8 
±2.1 
8.4 
±2.1 
8.8 
±2.6 
6.8 
±1.8 
6.9# 
±1.9 
6.2# 
±1.3 
6.4# 
±1.7 
6.3# 
±1.6 
6.0# 
±1.5 
5.4# 
±1.9 
5.6# 
±1.5 
  Pre Im   5min  10min 2min 4min 6min 8min 10 
min 
1h 2h 3h 
Subjective 
Shivering 
CON 1 
±0 
  1 
±0 
 1 
±0 
1 
±0 
1 
±0 
1 
±0 
1 
±0 
1 
±0 
1 
±0 
1 
±0 
1 
±0 
(AU) CWI 1 
±0 
  2 
±1 
 2 
±1 
2 
±1 
2 
±1 
2 
±1 
2 
±1 
2 
±1 
1 
±0 
1 
±0 
1 
±0 
Values are mean ± SD. A main effect for condition and time along with a significant interaction between condition and time was found for V̇O2 
(P < 0.05). # Significant difference from pre-immersion (P < 0.05). PreIm = Pre Immersion, AU = arbitrary units. 
 
 
 
 
 
 
 Table 3 : Plasma derived metabolic and hormonal markers measured Pre-Exercise, Post-Exercise, +1 h, +2 h, +3 h following the cessation of 
exercise (n = 9 mean ± SD). * Significantly different from Pre-Exercise (P < 0.05), # Main interaction effect present (P = 0.026).  
 
  Pre-Exercise Post-Exercise +1 h +2 h +3 h 
Glucose (mmol·L-1) CON 5.50 ± 0.50 6.15 ± 0.37* 5.28 ± 0.32* 5.20 ± 0.52* 5.29 ± 0.36* 
 CWI 5.77 ± 0.57 6.06 ± 0.89* 5.30 ± 0.85* 5.25 ± 0.85* 5.32 ± 0.76* 
Lactate (mmol·L-1) CON 1.41 ± 0.40 8.23 ± 3.97* 1.86 ± 0.94 1.32 ± 0.44 1.36 ± 0.47 
 CWI 1.68 ± 0.69 7.47 ± 3.42* 2.78 ± 1.55 1.75 ± 0.65 1.44 ± 0.38 
NEFA (mmol·L-1) CON 0.60 ± 0.24 0.83 ± 0.26 1.39 ± 0.23* 1.44 ± 0.35* 1.49 ± 0.43* 
 CWI 0.65 ± 0.24 0.87 ± 0.38 1.64 ± 0.29* 1.39 ± 0.33* 1.50 ± 0.29* 
Glycerol (µmol·L-1) CON 44.94 ± 23.70 290.22 ± 99.92* 120.78 ± 51.52* 114.63 ± 50.00* 102.36 ±45.79* 
 CWI 41.11 ± 22.02 273.81 ± 52.52* 155.36 ± 38.32* 116.00 ± 52.46* 97.21 ± 30.75* 
Insulin (U·mL-1) CON 12.88 ± 6.86 11.55 ± 3.06 13.50 ± 4.08 12.55 ± 4.68 12.79 ± 6.47 
 CWI 14.04 ± 5.02 10.32 ± 4.02 11.61 ± 5.67 11.57 ± 3.61 6.53 ± 1.17 
Normetanephrine 
(pmol·L-1) 
CON    # 699.81 ± 197.68 1728.39 ± 481.09* 914.39 ± 275.69* 738.82 ± 247.92* 634.93 ± 204.63 
 CWI     # 553.09 ± 237.16 1883.33 ± 655.17* 1128.64 ± 531.83* 1033.08 ± 461.74* 919.57 ± 371.43 
Metanephrine 
(pmol·L-1) 
CON 263.94 ± 133.08 535.48 ± 145.29* 305.63 ± 98.15* 272.43 ± 49.25 232.32 ± 72.05 
 CWI 245.67 ± 80.04 506.73 ± 149.39* 321.30 ± 88.33* 258.46 ± 75.54 268.76 ± 70.56 
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